

GSK429286A

Catalog No: tcsc0095



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

864082-47-3

Formula:

$C_{21}H_{16}F_4N_4O_2$

Pathway:

TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage

Target:

ROCK;ROCK;ROCK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 51 mg/mL (117.95 mM)

Observed Molecular Weight:

432.37


Product Description

GSK429286A is a selective inhibitor of **ROCK1** with an **IC₅₀** value of 14 nM.

IC50 & Target: IC50: 14 nM (ROCK1)^[1].

In Vitro: GSK429286A at 1 μ M reduces ROCK2 activity over 20-fold, under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced \sim 5-fold. GSK429286A is a more selective ROCK2 inhibitor than the widely utilized ROCK inhibitor Y-27632 as assessed on kinase-specificity panel, and does not significantly inhibit LRRK2 even at doses as high as 30 μ M (500-fold higher than IC₅₀ of inhibition of ROCK2). GSK429286A slightly inhibits RSK and p70S6K with IC₅₀ of 0.78 μ M and 1.94 μ M, respectively. GSK429286A significantly inhibits rat aortic ring dilation with IC₅₀ of 190 nM^[2].

In Vivo: GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats. Oral administration of GSK429286A at single doses of 3-30 mg/kg dramatically reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs) in a dose-dependent manner, with a maximum decrease of 50 mmHg after approximately 2 hours treatment at dose of 30 mg/kg^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!